Trabectedin
- Generic Name
- Trabectedin
- Brand Names
- Yondelis
- Drug Type
- Small Molecule
- Chemical Formula
- C39H43N3O11S
- CAS Number
- 114899-77-3
- Unique Ingredient Identifier
- ID0YZQ2TCP
- Background
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machin...
- Indication
用于治疗急性淋巴母细胞白血病、晚期软组织肉瘤及复发卵巢癌。
- Associated Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Platinum Sensitive Relapsed Ovarian Cancer, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Associated Therapies
- -
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 16
- Registration Number
- NCT04305548
- Locations
- 🇮🇹
Nuovo Ospedale di Prato, Prato, Firenze, Italy
🇮🇹Policlinico Universitario Campus Biomedico, Roma, RM, Italy
🇮🇹Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT04076579
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 200
- Registration Number
- NCT04008238
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03884972
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 9
- Registration Number
- NCT03690739
- Locations
- 🇩🇪
Sozialstiftung Bamberg, Bamberg, Germany
🇩🇪Kreiskrankenhaus "Johann Kentmann", Torgau, Germany
🇩🇪Hochtaunus-Kliniken, Bad Homburg, Germany
Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 92
- Registration Number
- NCT03590210
- Locations
- 🇩🇪
Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum Berlin-Brandenburg, Bad Saarow, Germany
🇩🇪Medizinische Fakultät "Carl Gustav Carus" der TU Dresden, Medizinische Klinik I, Dresden, Germany
🇩🇪Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin C, Hämatologie und Onkologie, Greifswald, Germany
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- University of Miami
- Registration Number
- NCT03437070
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03397186
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT03138161
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- National Center for Tumor Diseases, Heidelberg
- Target Recruit Count
- 102
- Registration Number
- NCT03127215
- Locations
- 🇩🇪
Universitätsmedizin der Johannes-Gutenberg-Universität Mainz, Mainz, Germany
🇩🇪Universitätsklinikum Frankfurt, Frankfurt, Germany
🇩🇪Medizinische Fakultät der TU Dresden, Dresden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.